Preparation for preventing and treating respiratory and gastrointestinal infectious diseases of bacterial and viral etiology in farm animals and method for preventing and treating respiratory and gastrointestinal infectious diseases of bacterial and viral etiology in farm animals

FIELD: veterinary science.

SUBSTANCE: the suggested preparation for preventing and treating respiratory and gastrointestinal infectious diseases of bacterial and viral etiology in farm animals contains tetracycline (oxytetracycline) (8-10%-solution) at the quantity of about 10-15 vol.%, polyethylene glycol (15-20%-solution) - about 10-15 vol.%, polyvinyl pyrrolidone (15-20%-solution) - about 10-20 vol.%, ethylene diamine tetraacetate (0.01-0.02%-Versen's solution) - about 10-15 vol.%, and, also, trypsin (0.01-0.25%-solution) - the rest. As for the method for preventing and treating the above-mentioned diseases, it deals with a single intramuscular injection of the present preparation for farm animals (predominantly, for piglets) at the dosage of about 0.5-1.0 ml/animal. The suggested preparation is of immunostimulating properties and provides efficient therapy of respiratory and gastrointestinal diseases of bacterial and viral etiology.

EFFECT: higher efficiency of prophylaxis and therapy.

2 cl, 6 tbl

 

The present invention relates to the field of veterinary immunology and chemotherapy, in particular to a drug for the treatment of respiratory and gastrointestinal bacterial and viral diseases of farm animals and to the way their prevention and treatment.

Currently, pulmonary and gastrointestinal diseases are widespread and cause significant damage resulting from the great loss and weight reduction of young farm animals.

Well-known drug for the treatment of respiratory and gastrointestinal infections of farm animals bacterial etiology - lieterally [1], which includes,%:

Levomycetin VDV4 g
Tetracycline ADV (oxytetracycline)4 g
Sulfadimidine ADV2 g
Ascorbic acid0.1 g
Novocaine1 g
The polyethylene glycol20 g
1,2 Propylene glycolTo 100 ml

Also known medication for the treatment of respiratory and gastrointestinal infections of farm animals bacterial etiology of Lieterally [2], including, g/100 ml:

Levomycetin succinate (ADV)3,0-5,0Tetracycline (oxytetracycline) (ADV)3,0-5,0Sulfatides (ADV)1.5 to 2.5Novocaine0,8-1,2Ascorbic acid0,08-0,12Tween - 80 (official)18,0-22,01,2 Propylene glycolTo 100 ml

Method of prevention and treatment is intramuscular drug application 2 to 3 times the introduction of calves, lambs and pigs in doses, respectively, of the body mass of animals [2. The prototype].

The objective of the research was to enlarge the range of immunological drugs and a drug, in addition to possessing immunostimulating effect of preventive and curative property against respiratory and gastrointestinal diseases in animals bacterial and viral etiology.

This was achieved by selecting the components of the proposed drug that includes:

an aqueous solution of polyethylene glycol and polyvinylpyrrolidone, a commercial solution of Versene, an aqueous solution of tetracycline and commercial trypsin solution, in the following ratio of components,%:

15-20%aqueous solution of p is litlington
(2000-6000 MM) (PEG)10-15
15-20%aqueous solution of polyvinylpyrrolidone
(280000-360000), (PVP)10-20
0,01-0,02% commercial solution of Versene10-15
8-10%aqueous solution of tetracycline10-15
0,01-0,25% KOMMERCHESKIY the trypsin solution
(100-128 ED) (himopsina, chymotrypsin)Rest

The proposed remedy is prepared as follows:

Example 1. In 100 ml of distilled water is made of 20 g PEG and 20 g of PVP, thoroughly mixed, after complete dissolution sterilized by autoclaving at 121°With 45 minutes.

Next, in a sterile vial is mixed by stirring with 20 ml of PEG and PVP, add 15 ml of 0.02%of Versene, and 10 g of tetracycline hydrochloride and 0.25%trypsin solution (100-128 ED), bringing the volume up to 100 ml

Thus obtained preparation is ready for use.

Shelf life: the product is 12 months when stored in the mode 3+6°C.

Were prepared and tested following the formulations of the drug - see table 1, 2 and 3.

Developed dosage forms have a high therapeutic and prophylactic efficacy, low toxicity and immune stimulating action of the M.

The proposed drug has a broad spectrum activity against bacterial and viral infections and is immune stimulator.

Entering into the composition of a 20%aqueous solution of PEG (MM - 2000-6000) about 23 ml causes necrobiosis or necrosis at the injection site, and the number below 10 ml does not provide the desired effect. Entering into the composition of a 20%aqueous solution of PEG provides the effect of prolongation. 20%aqueous solution of PVP (MM - 28000-360000)in excess of 23 ml in part, calls for the injection of necrotic and degenerative changes in tissues, fewer (10 ml) - low level of therapeutic effect.

The composition containing 20%solution of PVP, has an immunostimulating effect.

0,02%commercial solution of Versene (ethylendiaminetetraacetic), (EDTA), present in the composition in quantities exceeding (15 ml), contributes to the development of necrosis and degeneration with subsequent atrophy of the tissues, and in small quantities (less than 10 ml), insufficient efficiency of recovery of animals.

Use as part of a 0.02%aqueous solution of Versene causes immunomodulatory effect, the destruction of microbes and viruses in the body.

10%aqueous solution of tetracycline (oxytetracycline) hydrochloride, exceeding the maximum level in the structure (15 ml) causes necrotic, necrobiotic and distrot the ical disorders, and in smaller quantities (less than 10 ml) - low treatment effect.

Use as part of a 10%aqueous solution of tetracycline hydrochloride provides a wide range of antimicrobial, antiviral actions.

Use in the composition of 0.25%trypsin solution provides the effect of prolongation and immunostimulation, as well as the destruction of viruses of microbes in the body.

Treatment and prevention the proposed medication is in the intramuscular or subcutaneous its use in diseases of the respiratory and gastrointestinal tract, etc. caused by viruses and microbes.

The drug is administered once in doses: for mice weighing 12-28 g 0,5-0,8 ml subcutaneously to rats weighing 100-200 g and Guinea pigs weighing 200-350 g - 0,5-0,8 ml and rabbits weighing 1.5 to 2.5 kg - 0.5-1.0 ml for pigs on the head of 0.5-1 ml

Cited specific examples of the method of treatment.

Example 1. Treatment of transmissible gastroenteritis rabbits (THC).

Were studied 3 groups of rabbits weighing 2-3 kg, 10 animals each: group 1 proposed drug (Powin-VM) was administered in the dose of 1 ml per head. When conducting repeated experiments, the dose ranged from 1-2 ml/goal. There are other formulations of the drug. Cm. table 1, 2, 3.

group 2 - the introduction of levorotation (LAC) in a volume of 1 ml/bird., Group 3 - 0.1 g/bird, tetracycline and 1 ml (the control).

The frequency and duration of treatment was as follows: 1st group - a single application for the entire course of treatment (5-7 days), 2-St - 2 times, with an interval of 3 days, 5-7 days, and in group 3, 2 times a day for 5-7 days. The results shown in table 4.

Were conducted immunological research to determine the effectiveness of the immune proposed drug. This research was carried out according to the standard technique: determination of antibody productive cells (AFC), the reaction of inhibition of migration of blood leukocytes (RTML), the reaction is spontaneous changes in the adhesion of leukocytes (RIPL).

This experiment was carried out in 90 heads 30 goals in each group, with triplicate study (results shown in table 4).

From the shown results on comparative determining therapeutic effectiveness may be noted the advantage of the proposed drug. Of the 30 patients - 29 goals recovered fully, that is to 96.6% treatment efficiency. This is 1.5 times higher than therapeutic activity LATS and 14.6 times - results of the treatment in the 3rd group (sanitation tetracycline).

It should be noted that in the group, sanitized proposed by the drug, there was no single case of recurrence of the disease, whereas in the group that received LAC, the recurrence rate ohvatila heads or 42.2% of the total number recovered.

The results of immunological studies on the comparison of the proposed and known drugs has allowed to identify a significant advantage of the first. Thus, the number of the KLA, as an indicator of humoral immunity in cases of applying the proposed drug, exceeded those indicators in the prototype 1.8, and in the analog - 2.6 times. Indicators RTML indicate that the braking index to 0.1% of phytohemagglutinin was 1.2 times more active in the treatment of the proposed drug in comparison with the prototype, and 1.3 times the equivalent. This indicates cellular stimulation of the proposed drug. The results for RIPL also represent the fact cellular stimulation of the proposed drug. The percentage of adhered leukocytes in the treatment proposed by the drug was 1.3 times higher in comparison with the prototype and 1.5 compared with the equivalent.

Thus, the tests of the comparative clinical effectiveness of the proposed drug has allowed to mention the high therapeutic effect in a single application, unlike single use LAC and repeated administration of tetracycline.

Example 2.

Comparative therapeutic efficacy of the proposed drug for pneumoenteritis in Guinea pigs.

In experiments were used by 25 heads of Guinea pigs, which amounted to three groups:

group 1 - treatment is suggested by the drug at a dose of 1 ml/bird., once intramuscularly, for the entire course of treatment (the drug table 2),

group 2 - treatment LEC at a dose of 1-2 ml/goal. once intramuscularly and

group 3 - intramuscular immunoglobulin in the volume of 3-5 ml/goal twice and 4th group - use of tetracycline in a dose of 0.1-0.3 g/bird., 2 times a day, intramuscularly. For the experimental animals were observed within 6-8 months in order to identify cases of recurrent respiratory and gastrointestinal system in Guinea pigs.

The results are presented in table 5.

The table analysis showed that therapeutic effect in the case of applying the proposed drug is 96,0%, which is more than 1.5 exceeds the data treatment in the 2nd group and about 2 times, the 3rd and 4th groups.

Observations were carried out over sanitized Guinea pigs all 4 groups (within 6-8 months) allowed to establish the absence of relapses in group 1. In 2, 3 and 4 groups, their number amounted to, respectively, 5 goals (38,4%), 4 goal. (34.3%) and 6 goal. (54.5 per cent) of the number of clinically Vigdorovich Guinea pigs.

It should be noted also good tolerability of the proposed drug in Guinea pigs during the onset of therapeutic effect. Comparing these results it can be noted that in group 1 the onset of therapeutic effect of the drug was noted after 6-10hours, while in the 2nd, 3rd and 4th groups after 12 to 15 and 16 and 22 hours, respectively. therapeutic effect of combined reading of the temperature of the body, shortness of breath, clinics respiratory syndrome, stop diarrhea, eating feed, General condition.

Draws attention to itself and such an important fact, as the rate of application of drugs, components 1 and 2 groups 1 times, 3-2 times and in 4-10-14 time. As a positive point to note and cheapness of the proposed drug.

Therapeutic efficacy of the proposed drug in the presence of politologicheskogo factor of disease was 96,0%. At the same time from application LETS, tetracycline and microglobulin was 2 times lower and, respectively, with 52.0%, 44.0% and 48.0 per cent.

Pavin-VM applied once intramuscularly to pigs in the four-day or 2-4 months of age, at a dose of 0.5-1.0 ml/goal., regardless of body weight.

The control group consisted of animals that received only the vaccine.

Prophylactic efficacy of the proposed drug for the pigs to prevent respiratory and gastrointestinal diseases bacterial and viral etiology is presented in table 6.

Analysis of the obtained results on the testing of Polina-VM" revealed its prospective value. The drug is used only once during the whole cultivation period and surrender to the meat.

<> The apparent low levels of mortality (3.7 times) and forced the slaughter of animals (0.3 times).

Cancelled the high survival rate of pigs (1.2 times), average daily gain (0.7 times), the weight of livestock at the time of meat (0.8 times).

Pavin-VM prevents viral and microbial diseases due to non-drug ingredients.

Adverse reactions not observed, as in the time of weaning, and at the age of 2-4 months. Animals that received Pavin-VM, much more.

Thus, the developed immunostimulant single application with the preventive purpose, Powin-VM, avoiding repeated use of traditional vaccines and other medications, improved livestock safety, weight gain, significantly reduced the mortality and forced slaughter of pigs that will allow you to pass the state an additional thousand tons of meat.

In all groups, sanitized proposed drug LAC and tetracycline in different species of laboratory and agricultural animals was launched (pigs) at varying etiology conducted microscopic examination of affected tissues (lungs, stomach, intestine, mammary gland, and so on). Made mikroskopische and electron microscope study of drugs prepared according to standard techniques. The results of the research showed that only groups of animals, CA the proposed new drug (Polynom-VM) marked not only the complete destruction and lysis of microorganisms, but structural changes of the cell wall from them. So, in particular, microbes revealed swelling, loosening and partial lysis of the outer shell, and viruses - swelling of virions, relief and refinement supercasino shell, and clumping of the nucleocapsid.

Based on the results of experiments on the application of the proposed drug can confidently say its following advantages:

- has a high therapeutic effect (95,0-96,0%) with broad etiological spectrum of pathogens (viruses, bacteria);

- harmless in a single muscle introduction of laboratory animals and agricultural animals was launched (pigs). Chemotherapeutic index was 5.5;

a single injection provides a full course of treatment for infectious diseases of different localization system;

the drug can be prepared in the laboratory and to maintain therapeutic activity 3+6°C for 12 months;

- has not only prolonged antibacterial, antiviral, and immune stimulating effects. In addition, it is able to neutralize the pathogen with the preservation of its antigenic structure in varying degrees, what is important in the context of developing a specific protection of the organism.

The proposed remedy to be applied the proposed method DL the prevention and treatment of pulmonary and gastro-intestinal diseases of bacterial and viral etiology in agricultural animals was launched, tested with positive results from 1990 to 2005 in Vladimir, Samara and Tver regions.

The preparation and the method of its application will be widely spread in pig farms and private sectors of the Russian Federation and will allow us to reduce the above-mentioned diseases and to increase the output of a full-fledged youngsters and meat.

Ask the drug to call PAVIN-VM developed according to the documentation.

Sources of information

1. Directory of domestic and foreign drugs. - M: IRIS PRESS, 1994, p.74.

2. RF patent №2214821, class a 61 K 31/00, And 61 R 1/00, 2003

Table 1
The components and sequence of their dissolutionRequired components per 100 ml (% vol.)
15%aqueous solution of PEG (2000-6000 MM)10 ml
15%aqueous solution of PVP (MM 280000-36000)10 ml
0,01%commercial solution of Versene10 ml
8%aqueous solution of tetracycline hydrochloride (oxytetracycline)10 ml
0,01%commercial solution of trypsin 128 UNITS (himopsina, chymotrypsin)To 100 ml
Table 2
The components and sequence of Aristomene Required components per 100 ml (% vol.)
20%aqueous solution of PEG (2000-6000 MM)15 ml
20%aqueous solution of PVP (MM 280000-360000)20 ml
0,025-tion of a commercial solution of Versene15 ml
10%aqueous solution of tetracycline hydrochloride (oxytetracycline)15 ml
0,25%commercial trypsin solution 100 U (himopsina, chymotrypsin)To 100 ml
Table 3
Specific examples of formulations of the drug (Powin-VM)
The components and sequence of their dissolutionRequired components per 100 ml (% vol.)
22%aqueous solution of PEG (2000-6000 MM)12.5 ml
23%aqueous solution of PVP (MM 280000-360000)15 ml
0,015%commercial solution of Versene12.5 ml
9%aqueous solution of tetracycline darklord (oxytetracycline)12.5 ml
0,15%commercial solution of trypsin 128 UNITS (himopsina)To 100 ml

Table 4
Comparative therapeutic efficiency of the medicines when transmissible gastroenteritis in rabbits.
№ p/pDrug nameThe results of the treatment
immunological status
number of goalsrecoveredPaloAOKRTMLREPL
goal.%goal.%(index)(index)%
1.The proposed remedy (Powin-VM)302996,613,358,24±5,40,61±0,02of 98.2±2,3
2.LAC301963,31136,632,15±2,70,79±0,0474,3±2,8
3.Tetracycline hydrochloride3026,62893,321,93±3,60,81±0,0265,8±4,0
Note: observation of clinically recovered (reconvalescence) amounted to 6-8 months.
Table 5
Treatment of pneumoenteritis in Guinea pigs
№ p/pDrug nameThe results of the treatment
clinically recoveredcase
Qtygoals%goals%
1.The proposed remedy (Powin-VM)252496,014
2.LAC251352,01248,0
3.Microglobulin251248,01352,0
4.Tetracycline251144,01456,0

Table 6
The test results of Polina-VM" on the pigs.
No.Indicators"Pavin-VM" Control (vaccines) against plague, respiratory diseases and other
1Dose (ml/bird)0,5-1,00,5-2,0
2The concentrations of drug14 or more times
3Number of goals at the beginning of the experiment11491201
4Number of goals at the end of the experiment1108884
5Integrity (%)96,373,6
6Average daily gain during fattening (g)622,75442,88
7The average weight at the time of the meat (kg)126,71120,63
8Mortality during the fattening (a goal./%)12 (5,2%)46 (19.4 per cent)
9Forced slaughter (animals)819

1. A drug for prevention and treatment of respiratory and gastrointestinal diseases bacterial and viral etiology of farm animals, including tetracycline (oxytetracycline), and polyethylene glycol, characterized in that it further comprises polyvinylpyrrolidone, chemical - commercial aqueous solution of Versene (this is indianinternet) and an aqueous solution of trypsin, when the following ratio of components,%:

15-20%aqueous solution of polyethylene glycol
(2000-6000 MM), (PEG)10-15
15-20%aqueous solution of polyvinylpyrrolidone
(MM 280000-360000), (PVP)10-20
0,01-0,02%commercial solution of Versene10-15
8-10%aqueous solution of tetracycline10-15
0,01-0,25%commercial solution of trypsin
(100-128 ED)Rest

2. Method of prevention and treatment of respiratory and gastrointestinal infectious diseases of bacterial and viral etiology of farm animals, mainly pigs, characterized in that the preparation described in claim 1 of the formula injected once intramuscularly at a dose of 0.5-1.0 ml on the head of a pig.



 

Same patents:

FIELD: veterinary science, infectious diseases.

SUBSTANCE: invention relates to the development of dry cultural virus vaccine against plague in small ruminant animals that possesses high immunogenicity, harmlessness, areactogenic properties for sheep and goats and low cost. Virus vaccine comprises lyophilized virus-containing material prepared on base of the strain "45G37/35-K" and protective medium in the volume ratio 1:1. As protective medium virus vaccine comprises medium of the following composition, wt.-%: enzymatic peptone, 9.8-10.2; lactose, 1.8-2.2, and distilled water, the balance. Vaccine is harmless, shows highly immunogenic properties and stable in storage.

EFFECT: improved and valuable properties of vaccine.

2 cl, 3 ex

FIELD: veterinary, in particular agents for prophylaxis and treatment of viral avian influenza.

SUBSTANCE: invention relates to application of birch bark extract as agent for prophylaxis and treatment of viral avian influenza.

EFFECT: antiviral agent of increased effectiveness.

7 tbl

FIELD: organic chemistry, medicine, virology.

SUBSTANCE: invention relates to novel 2-cycloalkylimino-5-(4-nitrophenyl)-1,3,4-thiadiazines of the general formula (I): wherein the group represents: piperidino-, pyrrolidino-, methylpiperazino-, hexamethyleneimino-group that possess the biological activity against smallpox virus. Invention provides preparing novel biological active compounds possessing an antiviral effect, in particular, against smallpox virus.

EFFECT: valuable biological and medicinal properties of compounds.

1 cl, 1 tbl, 4 ex

FIELD: medicine, in particular surgery, oncology.

SUBSTANCE: claimed method includes immunotherapy, namely on day before operation reaferonum-EC-lipint in dose of 1000-15000 U/kg is perorally administrated to patient. Then in postoperative period blood sampling, extracorporal incubation of leucocytes with imunofan, and intravenous drop administration are carried out. Further for 5 days after operation reaferonum-EC-lipint is perorally administrated to patient dose of 1000-15000 U/kg one time per day. Method of present invention may be used in treatment of patients after radiotherapy in postoperative period. Furthermore method makes it possible to decrease of therapy time by 1.6 times, to reduce total accident number by 2.3 times and decrease of mortality by 2 times.

EFFECT: improved method for rectal cancer treatment.

3 ex, 1 tbl

FIELD: medicine, in particular agent for treatment of hepatitis, toxoplasmosis, cytomegaloviral infection and influenza.

SUBSTANCE: claimed agent contains physiological saline for intravenous administration, comprising hydrogen peroxide, 0.2 % riboxine solution and decoction of liquorice roots in specific ratio.

EFFECT: non-toxic and effective agent for treatment of abovementioned diseases.

7 ex

FIELD: medicine, biotechnology, healthy medical and veterinary preparations.

SUBSTANCE: claimed method includes exposing of aqueous isotonic solution of sugar-containing raw materials such as mixture of glucose and fructose in mass ratio of 1:1 with gamma-irradiation in absorbed dose of 25-40 kGy.

EFFECT: agent of standard composition with high antiviral and hepatoprotective action.

2 tbl, 2 ex

FIELD: medicine, neurology, virology.

SUBSTANCE: invention relates to treatment of neurological diseases caused by herpes virus, such as Bell's paralysis, Hunt's disease, herpetic encephalitis accompanying with damage of cerebral nerves. Invention involves using 1,4-dihydropyridine blockers of calcium channels, such as felodipine, nifedipine, nimodipine, nisodipine being taken preferably in combination with herpes virus antagonist. Invention provides repairing damaged cerebral nerves by topical expanding arteriols and recovery of local microcirculation based on specific competitive interaction of definite groups of calcium blockers of 1,4-dihydropyridine type with vasoconstrictor endothelin.

EFFECT: enhanced effectiveness of treatment.

47 cl, 2 dwg, 1 ex

FIELD: medicine, pharmacy.

SUBSTANCE: invention relates to a cycloferon-containing medicinal agent used in prophylaxis and treatment of influenza and acute respiratory diseases, herpetic infection, chronic viral hepatitis B and C and prophylaxis of oncological diseases. Agent comprises a physiological solution in the following ratio of components: 10-29 - 10-2 mg of cycloferon in 1 ml of physiological solution. Also, invention relates to a method for preparing this medicinal agent. Proposed medicinal agent enhances antiviral and antitumor activity of natural killers by 1.8-fold, not less.

EFFECT: improved preparing and using method, valuable medicinal properties of agent.

7 cl, 1 dwg, 19 ex

FIELD: veterinary science.

SUBSTANCE: it is necessary to inject birch bark extract for the animal at the dosage of 20 or 40 mg/kg body weight. The present innovation enables to increase leukocytic immunocompetence that, in its turn, prevents viral proliferation and disease relapses.

EFFECT: higher efficiency of therapy.

2 cl, 1 dwg, 4 ex

FIELD: medicine.

SUBSTANCE: the suggested strain refers to DNA-containing Adenoviridae type being of cubic type of symmetry, has no supercapsid membrane, virions sizes - 70-80 nm, shape - icosahedral. Moreover, it is resistant to the temperature of 56°C for 30 min, not less, and to the action of both ether and chloroform. It is inactivated with formalin, theotropin, dimer ethylenimine. The strain is cultivated in hepatic cell culture of hen's embryos, about 72-96 h after infection it causes characteristic foci of granulation (cells' rounding), the formation of separate rounded cells and foci of cell degeneration. Viral titer is within 105.5 TCD50/ml. The strain enables to reproduce different forms of the disease mentioned for experimental investigations, it is highly useful for manufacturing certain diagnostic kits and vaccines, moreover, being of high antigenic and immunogenic activity.

EFFECT: higher efficiency.

2 ex

FIELD: medicine.

SUBSTANCE: method involves carrying out leukocytic plasmapheresis with at least 100 ml patient blood in two-stage sequential centrifuging at 800 rpm during 10 min and 2000 rpm during 10 min. Antimicrobial preparation is added to autoleukocytes. The autoleukocytes are irradiated with helium-neon laser with 2.2 mW power, wavelength of 0.63 mcm and exposure time of 10 min. The autoleukocytes with the antimicrobial preparation adsorbed thereon are intravenously introduced introduced to the patient every day once a day during 7 days.

EFFECT: enhanced effectiveness of treatment; retained antimicrobial properties with increased adsorption on leukocytes.

FIELD: medicine, otorhinolaryngology.

SUBSTANCE: invention relates to a method for treatment of acute suppurative maxillary sinusitis. Method involves applying copper-silver applicators on region of natural anastomosis and "fossa canina" for 8 h or washing out maxillary sinus with physiological solution with addition citric acid (100 mg/l), copper ions (24-25 mg/l) and silver ions (0.004-0.005 mg/l) or using the combination of copper-silver applicators and washing out maxillary sinus as said above. Such performance of method excluding using the external electric filed provides the effective treatment based on antibacterial, antioxidant, immunomodulating and anti-inflammatory properties of copper that are enhanced in the presence of silver ions significantly.

EFFECT: enhanced effectiveness of treatment method.

3 cl, 2 ex

FIELD: medicine, surgery.

SUBSTANCE: invention relates to a method for treatment of biliary peritonitis. Method involves abdominal cavity sanitation with furaciline, a single intravenous administration of 0.04% sodium hypochlorite solution in a patient as measured 1/10 of volume of circulating blood in patient body, and additional intramuscular administration of 10% alpha-tocopherol solution in 5-6 h as measured 100 mg per 24 h. In the following 24 h sodium hypochlorite and alpha-tocopherol solutions in above given doses are administrated in a single dose with simultaneous administration of cefatoxime in the dose 1 g, 4 times per 24 h and dalargin in the dose 2 mg per 24 h. Method provides normalization of indices of antioxidant system for early period, recovery of cell membranes and penetrability of vessels, decreasing symptoms of endocrine intoxication.

EFFECT: enhanced effectiveness of treatment method.

2 cl, 2 ex

FIELD: microbiology.

SUBSTANCE: the suggested vaccine contains the mixture of suspensions of microbial cells of Vibrio anguillarum N2 strain and Vibrio anguillarum VUR-19 strain taken at equal ratio at concentration being about 80-100 bln microbial cells/cu. cm nutritive medium. The present vaccine is of high prophylactic and curative activity.

EFFECT: higher efficiency.

2 ex

FIELD: medicine, surgical stomatology.

SUBSTANCE: one should apply sodium hypochlorite solution (SHC) as antibacterial, disintoxicative and immunotropic preparation, with the help of which before operative interference one should infiltrate tissue along the periphery of inflammatory infiltrate. After operation, before applying secondary sutures it is necessary to carry out dialysis of purulent wound with SHC. Simultaneously, one should conduct total hemocorrection due to intravenous injection of extracorporally oxidized autoblood for 6 d, daily, correspondingly: 3 ml SHC + 18 ml blood; 6 ml SHC + 15 ml blood; 9 ml SHC + 2 ml blood; 12 ml SHC + 9 ml blood; 15 ml SHC + 6 ml blood; 18 ml SHC + 3 ml blood, and, additionally, 2 h later it is necessary to inject intravenously 0.03%-SHC solution at about 3-4 ml/kg body weight by performing intracorporal blood oxidation. The innovation provides complex local and total disintoxicative, immunotropic and reparative impact at availability of antibioticoresistance that leads to shortened terms of therapy (by 6.9 d, on average) and, also, economy of payments for treating 1 patient at the volume of 2947 rubles.

EFFECT: higher efficiency of therapy.

2 ex, 1 tbl

Brobiotic // 2284354

FIELD: biotechnology, microbiology.

SUBSTANCE: invention proposes the strain Lactobacillus fermentum ME-3 DSM 14241 isolated from feces of health one year-old Estonian baby. The strain elicits high antibacterial effect in strain Escherichia coli, Shigella sonnei, Staphylococcus aureus, Salmonella typhimurium 1 and 2 and moderate activity against strain Helicobacter pylori, and it elicits also activity of [Mn]-dependent superoxide dismutase. Both its lysates and intact cells show antioxidant activity, increases the ratio reduced glutathione to oxidized glutathione in serum blood and able to trap toxic hydroxyl radicals. The strain L. fermentum ME-3 DSM 14241 is used as a probiotic, in preparing functional foodstuffs (yogurt, cheese) and non-foodstuffs (tablets, capsules), for prophylaxis of intestine and urinary infections being both for prophylaxis and treatment of chronic diseases caused by the prolonged oxidative stress. The strain elicits high antibacterial effect that promotes to prevention of pathogens multiplication in foodstuffs fermented by this strain and prevents infections associated with feeding.

EFFECT: valuable properties of probiotic.

4 cl, 6 tbl, 1 ex

FIELD: immunology, biotechnology, microbiology, pharmacy.

SUBSTANCE: invention reports variants of proteins obtained from Neisseria meningitides that elicit antigenic properties and possess the general antigenic determinants. Amino acid sequence of these proteins is given in the invention description. Invention discloses variants of nucleic acids encoding indicated proteins. Invention describes variants of a pharmaceutical composition comprising the effective amount of any of indicated proteins or effective amount of any of disclosed nucleic acids encoding indicated proteins. Pharmaceutical compositions are used as vaccine or immunogenic composition in treatment and prophylaxis of infection caused by Neisseria microorganism and as a diagnostic reagent for detection of Neisseria microorganisms. Invention proposes a method for treatment of infection caused by Neisseria microorganism. Using the invention provides carrying out diagnosis and prophylaxis of disease mediated by Neisseria meningitides.

EFFECT: valuable medicinal properties of peptides.

21 cl, 2 tbl, 1 ex

FIELD: organic chemistry, chemical technology.

SUBSTANCE: invention relates to novel 1,2,3-tris-[(ammonio)methylcarbonyloxypoly(alkyleneoxy)]-propane trichlorides of the general formula:

wherein at -X+ as -N+R1RR, R1 = R2 mean hydrogen atom (H), R3 means aliphatic hydrocarbon radical comprising 10-16 carbon atoms, a + c + e (the general degree of oxypropylation) = 49,b + d + f (the general degree of oxyethylation) = 0; at -X+ as -N+R1R2R3, R1 = R2 mean H, R3 means aliphatic hydrocarbon radical comprising 10-16 carbon atoms, a + c + e = 55, b + d + f = 0; at -X+ as -N+R1R2R3, R1 = R2 mean H, R3 means aliphatic hydrocarbon radical comprising 10-16 carbon atoms, a + c + e = 80, b + d + f = 24; at -X+ as -N+R1R2R3, R1 = R2 mean H, R3 means aliphatic hydrocarbon radical comprising 10-16 carbon atoms, a + c + e = 90, b + d + f = 27; at -X+ as -N+R1R2R3, R1 = R2 means H, R3 means phenyl, a + c + e = 80, b + d + f = 24; at -X+ as -N+R1R2R3, R1 = R2 mean H, R3 means phenyl, a + c + e = 90, b + d + f = 27; at -X+ as , a + c + e = 80, b + d + f = 24; at -X+ as , a + c + e = 90, b + d + f =27. Also, invention relates to a method for synthesis of these compounds. Method involves interaction of 1,2,3-tris-[hydroxypoly(alkyleneoxy)]-propane of the formula:

wherein a + c + e = 49-90, b + d + f = 0-27 with monochloroacetic acid in the presence of acidic catalyst, in boiling organic solvent medium with azeotropic removal of water formed and the following treatment of synthesized reaction product in polar solvent medium at heating with amino-compounds of the formula: NR1R2R3 wherein R1 = R2 mean H, R3 means aliphatic hydrocarbon radical comprising 10-16 carbon atoms, phenyl, or morpholine of the formula:

in the following mole ratios of reagents - propane hydroxyl derivative : monochloroacetic acid : amino-compound or morpholine = 1:(3.0-3.2):(3.0-3.2), respectively. New compounds show the bactericidal and fungicide activity and properties of demulsifying agents for petroleum emulsions.

EFFECT: improved method of synthesis, valuable properties of compounds.

7 cl, 3 tbl, 8 ex

FIELD: pharmaceutical industry.

SUBSTANCE: claimed composition contains Fructus Capsici, valerian alcohol tincture (Tinctura Valerianae), 70 % ethanol, Analginum, and distilled water in certain ratio. Method for production of said composition includes overflowing of Fructus Capsici with 70 % ethanol, followed by addition of valerian alcohol tincture and Analginum, preliminary dissolved in distilled water. Mixture is decocted for 13-15 days and filtered. Disclosed is method for treatment of skin foul diseases by application of abovementioned composition.

EFFECT: effective composition for treatment of skin foul diseases.

3 cl, 1 tbl, 3 ex

FIELD: pharmaceutical industry.

SUBSTANCE: method for granulation of non-dehydrated azitromicine includes mixing of non-dehydrated azitromicine particles with granulating amount of non-aqueous granulating liquid followed by drying of wet granules to remove non-aqueous granulating liquid. Non-dehydrated azitromicine is selected from group containing from hemi-ethanol solvate of azitromicine monohydrate, hemi-n-propanol solvate of azitromicine monohydrate, azitromicine sesquihydrate, and hemi-isopropanol solvate of azitromicine monohydrate. Also disclosed are pharmaceutical compositions containing granules of non-dehydrated azitromicine and method for treatment of protosoal or bacterial infections in mammalian by administration of said pharmaceutical composition.

EFFECT: granules of non-dehydrated azitromicine with improved quality.

10 cl, 8 tbl, 9 ex

FIELD: pharmaceutical industry, in particular mucolytic pharmaceutical agent.

SUBSTANCE: claimed composition contains therapeutically effective amount of bromohexin as active ingredient and sugar, starch and stearinic acid salt as target additives. Pharmaceutical composition is provided in form of tablets.

EFFECT: composition with improved physical and pharmaceutical properties, such as dissolving and active ingredient releasing.

8 cl, 2 tbl, 4 ex

Up!